Streetbeat News

Products Services

NIO

NIO Inc's shares are trading higher after the company reported an increase in vehicle deliveries for June and Q2. The company delivered 10,707 vehicles in June, up from 6,155 in May, and a total of 23,520 for Q2. The company also launched the ET5 Touring and started ramping up deliveries of its ES8 SUV in June. The rise in NIO's stock is also in sympathy with Tesla, which reported strong Q2 delivery numbers.

Portfolio Pulse from Adam Eckert

July 03, 2023 | 12:17 pm

DASH

KMX

MRNA

WMT

Insiders at Moderna, Inc. (MRNA), DoorDash, Inc. (DASH), CarMax, Inc. (KMX), and Walmart Inc. (WMT) have recently sold shares. Moderna submitted a regulatory application to the European Medicines Agency for an updated COVID-19 vaccine. DoorDash is offering more choices for consumers and Dashers at roughly the same cost. CarMax reported better-than-expected Q1 EPS and sales results. Real Good Food Company is expanding its Breaded Chicken and Asian Entrees platforms into Walmart stores nationwide.

Portfolio Pulse from Lisa Levin

July 03, 2023 | 12:16 pm

WIMI

WiMi Hologram Cloud is developing a digital twin-based human-robot collaboration system. This technology is expected to enhance the company's offerings in the hologram and AR market.

Portfolio Pulse from Bill Haddad

July 03, 2023 | 12:03 pm

RMED

Ra Medical Systems, Inc. (NYSE:RMED) is expanding its international distribution in anticipation of the receipt of the CE Mark for its new device, LockeT, expected in Q3 2023. The company has entered into a distribution agreement with Medilynq for the Middle East and is working with Bioline in Spain. RMED is also in the process of working toward agreements in Mexico, Peru, Chile, Brazil, Australia, Hong Kong, Thailand, and Malaysia.

Portfolio Pulse from Happy Mohamed

July 03, 2023 | 12:03 pm

DERM

Journey Medical Corporation (NASDAQ:DERM) announced that it expects topline results from the Phase 3 clinical trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea to be announced the week of July 10, 2023. The trials are expected to support a New Drug Application submission in the United States and a Marketing Authorization Application in Europe. DFD-29 is being developed in collaboration with Dr. Reddy's Laboratories Ltd.

Portfolio Pulse from Happy Mohamed

July 03, 2023 | 12:02 pm

AIHS

CARV

CWD

WDH

Four financial stocks, Carver Bancorp, Inc. (CARV), Waterdrop Inc. (WDH), Senmiao Technology Limited (AIHS), and CaliberCos Inc. (CWD), are considered oversold with their Relative Strength Index (RSI) values below 30. This indicates potential for price recovery in the short term. CARV's stock dropped 34% over the past month, WDH agreed to acquire Cunzhen Qiushi, AIHS reported 0.8 million completed orders for May 2023, and CWD's Q1 revenue increased by 21.5% YoY.

Portfolio Pulse from Lisa Levin

July 03, 2023 | 11:50 am

MCHP

Microchip Technology Inc. has announced a $300 million multi-year investment to expand its operations in India. The investment will be used to increase the company's research and development capabilities and expand its design centers in the country.

Portfolio Pulse from Bill Haddad

July 03, 2023 | 11:31 am

APLD

HPE

Applied Digital Corporation (APLD) has partnered with Hewlett Packard Enterprise Company (HPE) to deliver energy-efficient supercomputers for large-scale AI applications. Applied Digital will use HPE's HPE Cray XD supercomputers, featuring NVIDIA H100 GPUs, to enhance its AI Cloud service. The partnership aims to provide customers with high performance, cost-effective solutions for compute and data-intensive needs.

Portfolio Pulse from Nabaparna Bhattacharya

July 03, 2023 | 11:20 am

KRYS

Krystal Biotech has initiated its Phase 1 CORAL-1/US study of KB407 for Cystic Fibrosis, with the first patient being dosed. The primary focus of the study will be the safety and tolerability of nebulized KB407, with data expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 11:04 am

NLSP

NLS Pharmaceutics has received approval from the FDA and IRB to proceed with Phase 3 clinical trials for Mazindol ER, a treatment for narcolepsy.

Portfolio Pulse from Bill Haddad

July 03, 2023 | 11:02 am